Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthtech Industry Analysis

UpdatedSep 02, 2026
DataAggregated Company Financials
Companies70
  • 7D9.3%
  • 3M46.0%
  • 1Y-12.2%
  • YTD11.3%

The Healthtech industry is up 9.3% in the last week, with Veeva Systems up 13%. During this same period, the Evolent Health underperformed, falling 12%. However, the industry is down 12% over the past year. Looking forward, earnings are forecast to grow by 20% annually.

Industry Valuation and Performance

Has the U.S. Healthtech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 02 Sep 2026US$70.5bUS$13.8b-US$248,211,114.0038.8x-284.2x5.1x
Fri, 31 Jul 2026US$54.2bUS$13.4b-US$387,972,179.0032.3x-139.8x4x
Sun, 28 Jun 2026US$48.3bUS$14.4b-US$748,582,179.0029.9x-64.5x3.4x
Tue, 26 May 2026US$44.7bUS$13.6b-US$505,552,326.0029.3x-88.5x3.3x
Thu, 23 Apr 2026US$47.9bUS$13.6b-US$417,856,415.0031.9x-114.5x3.5x
Sat, 21 Mar 2026US$49.9bUS$13.6b-US$387,248,688.0032.9x-128.9x3.7x
Mon, 16 Feb 2026US$47.2bUS$13.6b-US$98,008,340.0038.6x-482.1x3.5x
Wed, 14 Jan 2026US$66.1bUS$13.6b-US$102,102,340.0052.2x-647.8x4.9x
Fri, 12 Dec 2025US$65.1bUS$13.6b-US$100,808,271.0055.9x-645.8x4.8x
Sun, 09 Nov 2025US$76.5bUS$13.1b-US$23,492,903.0061.6x-3258.4x5.9x
Tue, 07 Oct 2025US$82.8bUS$13.1b-US$211,110,296.0060.7x-392.2x6.3x
Thu, 04 Sep 2025US$76.5bUS$13.2b-US$285,313,296.0054.8x-268.3x5.8x
Sat, 02 Aug 2025US$77.0bUS$13.3b-US$582,741,447.0058.9x-132.1x5.8x
Mon, 30 Jun 2025US$78.9bUS$13.2b-US$1,382,394,447.0055.4x-57.1x6x
Wed, 28 May 2025US$67.1bUS$13.1b-US$1,464,889,073.0053x-45.8x5.1x
Fri, 25 Apr 2025US$66.6bUS$13.2b-US$1,417,865,959.0052.5x-47x5.1x
Sun, 23 Mar 2025US$70.6bUS$13.2b-US$1,405,690,435.0058.7x-50.2x5.4x
Tue, 18 Feb 2025US$77.2bUS$12.9b-US$1,604,881,514.0064.4x-48.1x6x
Thu, 16 Jan 2025US$64.5bUS$12.9b-US$1,638,075,364.0054.2x-39.4x5x
Sat, 14 Dec 2024US$68.9bUS$12.9b-US$1,644,592,390.0055.8x-41.9x5.4x
Mon, 11 Nov 2024US$69.3bUS$12.8b-US$1,677,294,370.0061.7x-41.3x5.4x
Wed, 09 Oct 2024US$63.0bUS$14.0b-US$3,264,827,208.0052.8x-19.3x4.5x
Fri, 06 Sep 2024US$65.3bUS$14.0b-US$3,301,808,821.0056.2x-19.8x4.7x
Sun, 04 Aug 2024US$57.8bUS$13.7b-US$3,169,950,669.0051.8x-18.2x4.2x
Tue, 02 Jul 2024US$56.7bUS$13.7b-US$1,909,009,047.0047x-29.7x4.1x
Thu, 30 May 2024US$57.8bUS$12.7b-US$1,885,422,856.0046.1x-30.7x4.5x
Sat, 27 Apr 2024US$57.2bUS$12.7b-US$1,631,005,679.0046.2x-35.1x4.5x
Mon, 25 Mar 2024US$64.4bUS$14.3b-US$1,502,658,316.0050.1x-42.9x4.5x
Wed, 21 Feb 2024US$64.3bUS$13.8b-US$5,661,107,794.0054x-11.4x4.7x
Fri, 19 Jan 2024US$72.3bUS$18.3b-US$5,780,316,752.0058.1x-12.5x3.9x
Sun, 17 Dec 2023US$68.9bUS$18.3b-US$5,781,192,665.0056.7x-11.9x3.8x
Tue, 14 Nov 2023US$62.3bUS$18.2b-US$5,939,477,037.0049.4x-10.5x3.4x
Thu, 12 Oct 2023US$72.3bUS$18.0b-US$5,559,240,965.0053x-13x4x
Sat, 09 Sep 2023US$75.2bUS$18.0b-US$5,515,729,389.0053.9x-13.6x4.2x
Price to Earnings Ratio

-13.6x


Total Market Cap: US$75.2bTotal Earnings: -US$5,515,729,389.00Total Revenue: US$18.0bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthtech Industry Price to Earnings3Y Average -140.1x202420252026
Current Industry PE
  • Investors are optimistic on the American Healthcare Services industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 4.6x is lower than the industry's current PS ratio of 5.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare Services industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 8.5% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.92%
Healthcare-2.56%
Healthtech9.32%
Healthtech9.32%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VEEV Veeva SystemsUS$279.2313.1%
+US$5.1b		3.4%PE44.6x
WAY Waystar HoldingUS$25.766.4%
+US$297.2m		-30.5%PE36.6x
DOCS DoximityUS$26.356.5%
+US$287.0m		-60.7%PE28.1x
SDGR SchrödingerUS$20.844.3%
+US$63.6m		9.1%PS6x
HTFL HeartFlowUS$50.431.1%
+US$47.0m		61.8%PS20.7x

Latest News

CTEV
US$39.35
Claritev
7D
4.5%
1Y
-43.2%
VEEV
US$279.23
Veeva Systems
7D
13.1%
1Y
3.4%
HTFL
US$50.43
HeartFlow
7D
1.1%
1Y
61.8%
SOPH
US$8.43
SOPHiA GENETICS
7D
-2.6%
1Y
151.5%
WAY
US$25.76
Waystar Holding
7D
6.4%
1Y
-30.5%
SCNX
US$0.37
Scienture Holdings
7D
-11.2%
1Y
-62.4%
DOCS
US$26.35
Doximity
7D
6.5%
1Y
-60.7%
Narrative Update • Aug 22

DOCS: AI Budget Share And Q1 AI Traction Will Drive Bullish Outlook

Analysts have lifted their Doximity price target from about $28.00 to roughly $29.78. This reflects updated models after Q1 results, differing views on AI monetization, and mixed opinions on how far current AI traction and pharma budget share can support growth amid rising competition and margin pressures.
LFMD
US$3.10
LifeMD
7D
-4.6%
1Y
-49.8%
Narrative Update • Aug 22

LFMD: GLP-1 Virtual Care And Pharmacy Expansion Will Support 2026 Outlook

The analyst price target for LifeMD has been cut, with our fair value estimate moving from $9.88 to $8.13 as analysts incorporate lower revenue growth and profit margin assumptions, along with a higher future P/E multiple following recent research updates. Analyst Commentary Recent Street research on LifeMD points to a more cautious stance on valuation, even as some analysts still see long term growth drivers in the business.
SDGR
US$20.84
Schrödinger
7D
4.3%
1Y
9.1%
Seeking Alpha • Aug 21

Schrodinger: The Software Business Is Stronger Than It Looks

Summary Schrodinger’s (SDGR) stock has rebounded in recent months, despite temporary revenue recognition headwinds from the shift to hosted software. Recent product launches such as Bunsen and predictive toxicology strengthen SDGR's software offering and could help mitigate concerns about AI disruption. Drug discovery activity remains strong, with growth increasingly driven by external collaborations as Schrodinger deemphasizes internal drug development. SDGR is undervalued, although a catalyst like a large partnership or positive clinical data will likely be needed before the stock moves significantly higher. Read the full article on Seeking Alpha
GDRX
US$3.46
GoodRx Holdings
7D
-0.4%
1Y
-19.5%
Narrative Update • Aug 21

GDRX: Pharma Direct GLP-1 Momentum And New Offerings Will Drive Future Upside

GoodRx Holdings' analyst price target has increased, moving from about $3.18 to roughly $4.03. Analysts point to updated models following Q2 results, including stronger GLP-1 momentum in Pharma Direct and revised views on sector peers.
CERT
US$8.10
Certara
7D
-0.5%
1Y
-24.0%
Narrative Update • Aug 20

CERT: Execution Risks And Leadership Turnover Will Constrain Future Returns

Certara's narrative fair value has been revised from $6.00 to $7.00 as analysts recalibrate models in response to mixed price target moves and updated views on profitability, growth trajectory, and peer valuation benchmarks. Analyst Commentary Recent research on Certara reflects a mixed but generally cautious tone.
DRIO
US$7.02
DarioHealth
7D
-5.0%
1Y
-23.3%
EVH
US$4.28
Evolent Health
7D
-12.5%
1Y
-55.5%
Seeking Alpha • Aug 13

Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming

Summary Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term debt and persistent GAAP losses. Management projects >25% revenue growth and adjusted EBITDA ≥$150m in 2027, aiming to improve leverage and capital structure. Industry recovery and strong specialty care revenue growth support the thesis, but EVH remains a high-risk, high-reward turnaround. Read the full article on Seeking Alpha
CCLD
US$2.26
CareCloud
7D
-6.2%
1Y
-38.6%
Analysis Article • Aug 09

CareCloud, Inc. (NASDAQ:CCLD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

It's been a good week for CareCloud, Inc. ( NASDAQ:CCLD ) shareholders, because the company has just released its...
HSTM
US$29.67
HealthStream
7D
2.8%
1Y
5.9%
PHR
US$11.84
Phreesia
7D
2.8%
1Y
-62.4%
Narrative Update • Jul 16

PHR: Securities Lawsuit And Weak Growth Visibility Will Pressure Shares

The analyst price target for Phreesia has been revised from $24 to $9, as analysts weigh lower modeled revenue growth, a reduced assumed future P/E multiple, and sector research that highlights competitive pressures, softer digital advertising trends, and limited visibility into a return to durable organic growth. Analyst Commentary on Phreesia Recent research on Phreesia points to a more cautious stance from several bearish analysts, with multiple downgrades and lower price targets reflecting concerns about growth visibility, competition, and the balance between profitability efforts and future expansion.